Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 6/20 | 0.40 |
| ▸ | SLC40A1 | Q9NP59 | 6/20 | 0.39 |
| ▸ | GLO1 | Q04760 | 3/20 | 0.38 |
| ▸ | TNF | P01375 | 1/20 | 0.38 |
| ▸ | CLK1 | P49759 | 1/20 | 0.37 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.37 |
| ▸ | MLNR | O43193 | 2/20 | 0.36 |
| ▸ | AKT1 | P31749 | 2/20 | 0.36 |
| ▸ | MTOR | P42345 | 2/20 | 0.36 |
| ▸ | EIF2AK3 | Q9NZJ5 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27118194 | 1.00 | PIK3CA (0.40) | PIK3CASLC40A1GLO1TNFCLK1 | |
| SCHEMBL30846415 | 0.89 | SLC40A1 (0.46) | PIK3CASLC40A1GLO1 | |
| SCHEMBL30846413 | 0.89 | SLC40A1 (0.46) | PIK3CASLC40A1GLO1 | |
| SCHEMBL27118191 | 0.89 | SLC40A1 (0.46) | PIK3CASLC40A1GLO1 | |
| SCHEMBL30846391 | 0.89 | PTGES2 (0.43) | PIK3CASLC40A1GLO1 | |
| SCHEMBL27118083 | 0.89 | PTGES2 (0.43) | PIK3CASLC40A1GLO1 | |
| SCHEMBL27118278 | 0.89 | SLC40A1 (0.41) | PIK3CASLC40A1GLO1 | |
| SCHEMBL30846237 | 0.89 | SLC40A1 (0.41) | PIK3CASLC40A1GLO1 | |
| SCHEMBL30846465 | 0.87 | SLC40A1 (0.40) | SLC40A1GLO1EIF2AK3 | |
| SCHEMBL27118193 | 0.87 | SLC40A1 (0.40) | SLC40A1GLO1EIF2AK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024044344-A1 | PYRIDINYLSULFONAMIDE COMPOUNDS AND THEIR USE IN THERAPY | HOTSPOT THERAPEUTICS, INC. (US) | 2024-02-29 | — | — | WO | disclosed |